Article Text

PDF
FRI0341 Do Patients with SLE at Onset Differ from Mimickers? A Comparison of Clinical and Serological Manifestations in A Multicenter Cohort To Inform The Development of New Classification Criteria for SLE
  1. Z. Touma1,
  2. K.H. Costenbader2,
  3. S. Johnson1,
  4. M. Mosca3,
  5. B.F. Hoyer4,
  6. S. Navara5,
  7. E. Bonfa6,
  8. R. Ramsey-Goldman7,
  9. J. Medina-Rosas1,
  10. C. Tani3,
  11. A. Fine8,
  12. S. Tedeschi2,
  13. V. Lorenzoni9,
  14. G.D. Sebastiani10,
  15. T. Dorner4,
  16. M. Aringer11,
  17. on behalf of the ACR/EULAR Group
  1. 1University of Toronto, Toronto, Canada
  2. 2Harvard Medical School, Boston, United States
  3. 3University of Pisa, Pisa, Italy
  4. 4Charité University Medicine, Berlin, Germany
  5. 5University of Santo Tomas, Manila, Philippines
  6. 6Universidade de São Paulo, São Paulo, Brazil
  7. 7Case Western Reserve University, Chicago
  8. 8Brigham and Women's Hospital, Boston, United States
  9. 9SSSUP, Pisa
  10. 10Osp. San Camillo, Roma, Italy
  11. 11Universitätsklinikum Carl Gustav Carus, Dresden, Germany

Abstract

Background Current SLE classification criteria may not classify patients with early SLE well. SLE mimickers can have an initial presentation similar to SLE and need to be distinguished from early SLE patients by classification criteria.

Objectives To describe the clinical and serological presenting manifestations of SLE at disease onset and those of SLE mimickers.

Methods We collected clinical and laboratory data on patients newly presenting with potential SLE (symptoms <12 months) within the past 3 years at centers in Europe (2), North America (3), South America (1) and Asia (1). Patients were diagnosed as SLE or mimicking conditions by clinical experts. We compared the presenting manifestations in SLE vs. mimickers. We examined combinations of autoantibodies, clinical and laboratory manifestations for their association with SLE vs. SLE mimickers in multivariable analyses.

Results Of 616 patients, 389 were diagnosed with SLE (89% female) and 227 were given other diagnoses (97% female). A smaller proportion of SLE patients than patients with mimicking conditions were White (55% vs. 90%). Mimickers included UCTD, Sjögren's syndrome, rheumatoid arthritis, scleroderma, and fibromyalgia. Clinical and autoantibodes presenting manifestations in new onset SLE and mimickers are represented in table 1. In univariable analyses, the following autoantibodies profiles were associated with SLE vs. mimickers: Profile 1 (ANA, anti-Sm, anti-Ro and anti-RNP; OR 3.49, 95% confidence interval [CI] 2.29–5.31) and Profile 2 (ANA, anti-cardiolipin IgG/IgM, Beta2 and lupus anticoagulant; OR 2.82, 95% CI 1.75–4.55). In multivariable analyses, the following autoantibodies profiles were associated with SLE vs. mimickers: Profile 1 (OR 3.02, 95% CI 1.90–4.80) and Profile 2 (OR 3.11, 95% CI 1.80–5.36). Adding hypocomplementemia to Profile 1 and 2 showed a high association with SLE [OR 3.40, 95%CI 2.21–5.22 and OR 2.41, 95%CI 1.53–3.80] respectively.

Table 1

Conclusions We identified clinical manifestations and autoantibodies more commonly associated with SLE than with mimickers at initial presentation. Autoantibody profiles particularly including ANA and especially in the presence of hypocomplementemia, showed associations with SLE.

Acknowledgement New SLE classification criteria for clinical research are being developed, sponsored by EULAR and ACR.

Disclosure of Interest None declared

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.